Abstract
Cancer cells acquire characteristics of deregulated growth, survival and increased metastatic potential. Genetic mutations that provide a selective advantage by promoting these characteristics have been termed ‘drivers,’ whereas mutations that do not contribute to disease initiation/progression are termed ‘passengers.’ The advent of high-throughput methodologies has facilitated large-scale screening of cancer genomes and the subsequent identification of novel somatic mutations. Although this approach has generated valuable results, the data remain incomplete until the functional consequences of these mutations are determined to differentiate potential drivers from passengers. ROCK1 is an essential effector kinase downstream of Rho GTPases, an important pathway involved in cell migration. The Cancer Genome Project identified three nonsynonymous mutations in the ROCK1 gene. We now show that these somatic ROCK1 mutations lead to elevated kinase activity and drive actin cytoskeleton rearrangements that promote increased motility and decreased adhesion, characteristics of cancer progression. Mapping of the kinase-interacting regions of the carboxy terminus combined with structural modeling provides an insight into how these mutations likely affect the regulation of ROCK1. Consistent with the frequency of ROCK1 mutations in human cancer, these results support the conclusion that there is selective pressure for the ROCK1 gene to acquire ‘driver’ mutations that result in kinase activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T et al. (2008). Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 29: 155–161.
Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC . (2004). Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 1705: 121–132.
Bokoch GM. . (1998). Caspase-mediated activation of PAK2 during apoptosis: proteolytic kinase activation as a general mechanism of apoptotic signal transduction? Cell Death Differ 5: 637–645.
Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF . (2001). Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3: 339–345.
Doki Y, Shiozaki H, Tahara H, Inoue M, Oka H, Iihara K et al. (1993). Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 53: 3421–3426.
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153–158.
Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y et al. (1997). p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404: 118–124.
Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S . (1999). An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221–225.
Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P et al. (2006). The structure of dimeric rock i reveals the mechanism for ligand selectivity. J Biol Chem 281: 260–268.
Kamai T, Arai K, Sumi S, Tsujii T, Honda M, Yamanishi T et al. (2002). The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 89: 449–453.
Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y et al. (2003). Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9: 2632–2641.
Kamai T, Yamanishi T, Shirataki H, Takagi K, Asami H, Ito Y et al. (2004). Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 10: 4799–4805.
Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M et al. (1996). Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 15: 2208–2216.
Nakajima M, Hayashi K, Egi Y, Katayama K, Amano Y, Uehata M et al. (2003). Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma. Cancer Chemother Pharmacol 52: 319–324.
Narumiya S, Tanji M, Ishizaki T . (2009). Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28: 65–76.
Ogawa T, Tashiro H, Miyata Y, Ushitora Y, Fudaba Y, Kobayashi T et al. (2007). Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant 7: 347–355.
Olson MF, Sahai E . (2009). The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 26: 273–287.
Sahai E, Marshall CJ . (2002). RHO-GTPases and cancer. Nat Rev Cancer 2: 133–142.
Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J . (2005). Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 201: 465–471.
Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP . (2000). Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269: 652–659.
Tan I, Seow KT, Lim L, Leung T . (2001). Intermolecular and intramolecular interactions regulate catalytic activity of myotonic dystrophy kinase-related Cdc42-binding kinase {alpha}. Mol Cell Biol 21: 2767–2778.
Wen W, Liu W, Yan J, Zhang M . (2008). Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of Rho kinases. J Biol Chem 283: 26263–26273.
Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E et al. (2008). Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 38: 810–817.
Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R et al. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5: 2158–2164.
Acknowledgements
This study was supported by Cancer Research UK and by a grant to MFO from the NIH (CA030721). Assistance with protein modeling was provided by Felix Krueger (Babraham Institute).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Lochhead, P., Wickman, G., Mezna, M. et al. Activating ROCK1 somatic mutations in human cancer. Oncogene 29, 2591–2598 (2010). https://doi.org/10.1038/onc.2010.3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.3
Keywords
This article is cited by
-
Development of a custom next-generation sequencing panel for the determination of bladder cancer risk in a Tunisian cohort
Molecular Biology Reports (2022)
-
Mutational drivers of cancer cell migration and invasion
British Journal of Cancer (2021)
-
RETRACTED ARTICLE: Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer
Mammalian Genome (2021)
-
microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma
Pathology & Oncology Research (2020)
-
ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson’s disease
Experimental & Molecular Medicine (2019)